Daily cardiology

📚 ESC 2025 Coverage: When Three Drugs Aren’t Enough: Exploring Baxdrostat in Resistant Hypertension by Dr. Ghanavati, Cardiovascular Specialist.

 📚 ESC 2025 Coverage: One Size Doesn’t Fit All: The TAILORED-CHIP Trial Rethinks Dual Antiplatelet Therapy in Complex PCI, by Dr. Bahadori, Cardiovascular Specialist.

📚 ESC 2025 Coverage: Post-Ablation Management Revisited: Is It Safe to Discontinue Oral Anticoagulation? by Dr. Mirzaeian, Fellowship of Electrophysiology.

 📚 ESC 2025 Coverage: Is Seeing Believing? Evaluating CT-Guided Follow-Up After Left Main Coronary Intervention, by Dr. Sezavar, Interventional Cardiologist.

 📚 ESC 2025 Coverage: From Normal to Optimal: Rethinking Potassium Targets in Arrhythmia-Prone Patients, by Dr. Bozorgi, Cardiac Electrophysiologist.

📚 ESC 2025 Coverage: Expanding the Benefit Zone: Can β Blockers Help Post-MI Patients with Mildly Reduced Ejection Fraction? by Dr. Yahyavi, Cardiovascular Researcher.

📚 ESC 2025 Coverage: The SMuRF-less Illusion: Inflammation Unmasks Hidden Cardiovascular Risk in Healthy Women, by Dr. Hafezi, Cardiovascular Specialist.

📚 ESC 2025 Coverage: A Classic Revived: Digitoxin Lowers Risk in HFrEF When Added to Modern Therapy, by Dr. Talasaz, Clinical Pharmacist.

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

📚 ESC 2025 Coverage: All at Once or One Step at a Time? Immediate Revascularisation Falls Short of Non-Inferiority in STEMI Patients, by Dr. Soltani Moghadam, Cardiovascular Researcher.

📚 ESC 2025 Coverage: Finding the Silent Beat: Remote ECG Screening Slightly Boosts Atrial Fibrillation Detection, by Dr. Tahmtan, Fellowship of Electrophysiology.

📚 ESC 2025 Coverage: Cholesterol Crushed, But Grafts Still Failed: Evolocumab Misses the Mark in NEWTON-CABG, by Dr. Ghavidel, Cardiovascular Surgeon.

📚 ESC 2025 Coverage: More Isn’t Always Better: Dual Antiplatelet Therapy Falls Short After CABG for ACS, by Dr. Mehrpouya, Interventional Cardiologist.

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum VICTORIA and VICTOR Clinical Trials 📚 ESC 2025 Coverage: Bridging Stability and Severity: Vericiguat’s Role Expands in Heart Failure Therapy, by Dr. Taghavi, Fellowship of Heart Failure.

Reduction of Antihypertensive Treatment in Nursing Home Residents 📚 ESC 2025 Coverage: Taking the Pressure Off, Gently: Can Fewer BP Pills Help Frail Elders Thrive? by Dr. Mansouri, Internal Medicine Specialist.

High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults 📚 ESC 2025 Coverage: Double the Dose, Double the Defense? by Dr. Soleimani, Cardiovascular Specialist.

Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction (TARGET-FIRST)

Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO)

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF RCT 📚 Impact 52: Finerenone and mode of death in HF: Where do we stand? A review by Dr. Soltani Moghadam, Cardiovascular Researcher.

📚 Impact 51: Intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants (DOACs), A review by Dr. Haeri, Neurologist.

💊 Hypertension and Hyperlipidemia at your fingertips! 5️⃣ H&H Academy in 7 minutes, episode 7.

📚 Impact 50: Thrombolysis before thrombectomy: A bridge not fallen, A review by Dr. Benam, Cardiovascular Specialist.

🫀Case Discussion 125: DVT Prophylaxis in Post-Ischemic Stroke Patients, by Dr. Bikdeli, Cardiovascular specialist.

SGLT2 inhibitors in CKD: are they really effective in all patients?

DOACs for Rheumatic Heart Disease-Associated AF Post-Bioprosthetic MVR